Technology News and Research

RSS

Cisco deploys Integrated Medical-Grade Network at HIAE

Cisco today announced the deployment of an Integrated Medical-Grade Network at the Albert Einstein Israeli Hospital (HIAE) in Sao Paulo city. The Hospital is recognized in Latin America for pioneering the innovative use of technology to streamline business processes and deliver value to its patients.

11 Sep 2009

TomoTherapy signs purchasing agreement with GNYHA Services

TomoTherapy Incorporated, maker of the TomoTherapy® treatment system for advanced, CT-guided radiation therapy, announced today that it has signed an equipment supply group purchasing agreement with GNYHA Services, Inc. Pursuant to this agreement, TomoTherapy technology will be made available at contracted rates to more than 220 member hospitals in New York, New Jersey, Pennsylvania and Puerto Rico.

11 Sep 2009

Drug manufacturers are seeking out needle-free systems

Many of the novel biopharmaceutical drugs developed now can only be delivered by injection, and this has biologic manufacturers seeking out the most patient-friendly options, including needle-free systems.

11 Sep 2009

Cardiac Network awaits servicing its agreement with AWH; continues to expand its technology development

Cardiac Network, Inc. (PINKSHEETS: CNWI) reported today that it is continuing the expansion of its technology development initiatives for its products and services in anticipation of servicing its agreement with American Wholesale Health, or AWH, that was announced on June 22, 2009.

11 Sep 2009

Campaign to educate customers on chronic pain management

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that it is launching a Direct Mail and Web campaign in an effort to educate customers on a recent report from the Center for Disease Control (CDC), stating that among all diabetics, 52% suffer from arthritis.

11 Sep 2009

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target.

11 Sep 2009

BioCrossroads report on the Warsaw orthopedics community statistics

Now generating more than $11 billion in annual revenues, the global orthopedics sector concentrated in Warsaw, Indiana, represents more than half the U. S. market share and more than one- third of the world's market for developing orthopedic medical devices.

11 Sep 2009

Merge Healthcare and Rosslyn Medical extends their partnership

Building on a successful distribution agreement established over the past three years, Merge Healthcare, a leading health IT solutions provider, and Rosslyn Medical, a large medical imaging solution provider serving the Russian market, have extended their partnership to expand the portfolio of Merge OEM products available to Rosslyn.

11 Sep 2009

KidneyTel system helps manage health issues faced by kidney patients

Kidney patients often have a number of serious chronic health issues in addition to their kidney disease. Fresenius Medical Care, the world’s leading renal therapies company, has developed the KidneyTel system to provide an integrated care solution to assist patients, their families and their providers in managing the full range of health issues that kidney patients face on a daily basis.

11 Sep 2009

SafeTrace Tx software deployed in Schuylkill Health of Pottsville

Global Med Technologies((R)), Inc. ("Global Med" or the "Company"), an international e-Health, medical information technology company, today announced that its Wyndgate Technologies division has licensed and deployed its SafeTrace Tx((R)) transfusion management software to Schuylkill Health of Pottsville, Pennsylvania.

11 Sep 2009

Abbott to acquire Evalve for $410 million

Abbott announced today a definitive agreement to acquire the outstanding equity of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of cardiac mitral valves.

10 Sep 2009

Scientist awarded grant to study the role of VENs in quick decision making

A scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has been awarded a $400,000 grant from the James S. McDonnell Foundation to help study a rare cell type that is believed to play a role in quick decision making and intuition. Abnormalities in this cell type have been seen in people suffering from autism and dementia.

10 Sep 2009

Vitro Diagnostics' novel stem cell technology for cancer treatment

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

10 Sep 2009

The first CardioGraft patch with MatrACELL technology implant performed

LifeNet Health, a leading allograft bio-implant company, announces the first implant of a CardioGraft(TM) allograft cardiac patch product with MatrACELL(TM)( )decellularization technology. The surgery was performed at Children's Mercy Hospital in Kansas City, Mo by Gary K. Lofland, MD, FACS, Section Chief, Cardiovascular Surgery at Children's Mercy Hospital in Kansas City, Mo, The Joseph Boon Gregg/Missouri Endowed Chair in Pediatric Cardiac Surgery, Professor of Surgery, UMKC.

10 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

NIH provides Inviragen second major grant to develop a dengue vaccine

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.

10 Sep 2009

Electronic health records: A focus for big tech companies

"On one proposal for health care reform at least, there is a rare bipartisan consensus: the push to computerize patient records," The New York Times reports. The federal recovery package sets aside $19 billion "to encourage doctors and hospitals to install and use electronic health records. So even as the Obama administration and Congress struggle with broad health policy legislation, the technology industry is pursuing the opportunity in digital health records as never before." The money will not be available until next year, but General Electric, I.B.M. and Verizon are all "hoping to get their share."

10 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

PinnacleCare and Champions Biotechnology collaborate to offer personalized oncology services worldwide

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company whose personalized oncology services division assists physicians by providing personalized treatment options for their cancer patients, has entered into a collaboration agreement with PinnacleCare, the pioneer and the leading private health advisory company in the world.

10 Sep 2009

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe’s proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.

10 Sep 2009